Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial.
Schmoll HJ, Wittig B, Arnold D, Riera-Knorrenschild J, Nitsche D, Kroening H, Mayer F, Andel J, Ziebermayr R, Scheithauer W. Schmoll HJ, et al. Among authors: nitsche d. J Cancer Res Clin Oncol. 2014 Sep;140(9):1615-24. doi: 10.1007/s00432-014-1682-7. Epub 2014 May 10. J Cancer Res Clin Oncol. 2014. PMID: 24816725 Free PMC article. Clinical Trial.
Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.
Hausmaninger H, Moser R, Samonigg H, Mlineritsch B, Schmidt H, Pecherstorfer M, Fridrik M, Kopf C, Nitsche D, Kaider A, Ludwig H. Hausmaninger H, et al. Among authors: nitsche d. Eur J Cancer. 1999 Mar;35(3):380-5. doi: 10.1016/s0959-8049(98)00397-9. Eur J Cancer. 1999. PMID: 10448286 Clinical Trial.
Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib.
Öcal O, Schinner R, Schütte K, de Toni EN, Loewe C, van Delden O, Vandecaveye V, Gebauer B, Zech CJ, Sengel C, Bargellini I, Gasbarrini A, Sangro B, Pech M, Malfertheiner P, Ricke J, Seidensticker M; SORAMIC study group. Öcal O, et al. Cancer Imaging. 2022 Jan 4;22(1):1. doi: 10.1186/s40644-021-00439-x. Cancer Imaging. 2022. PMID: 34983668 Free PMC article.
[Hairy cell leukemia].
Nitsche D, Tschurtschenthaler G, Michlmayr G. Nitsche D, et al. Wien Med Wochenschr. 1984 Jun 15;134(11):245-50. Wien Med Wochenschr. 1984. PMID: 6464470 German. No abstract available.
[Results of cytostatic polychemotherapy in non-Hodgkin lymphomas].
Kratzer H, Hehenwarter W, Denz H, Bliem J, Tschurtschenthaler G, Nitsche D, Huber H, Michlmayr G. Kratzer H, et al. Among authors: nitsche d. Wien Klin Wochenschr. 1983 Aug 26;95(16):558-62. Wien Klin Wochenschr. 1983. PMID: 6689099 German.
Guidelines for mouse and human DC functional assays.
Clausen BE, Amon L, Backer RA, Berod L, Bopp T, Brand A, Burgdorf S, Chen L, Da M, Distler U, Dress RJ, Dudziak D, Dutertre CA, Eich C, Gabele A, Geiger M, Ginhoux F, Giusiano L, Godoy GJ, Hamouda AEI, Hatscher L, Heger L, Heidkamp GF, Hernandez LC, Jacobi L, Kaszubowski T, Kong WT, Lehmann CHK, López-López T, Mahnke K, Nitsche D, Renkawitz J, Reza RA, Sáez PJ, Schlautmann L, Schmitt MT, Seichter A, Sielaff M, Sparwasser T, Stoitzner P, Tchitashvili G, Tenzer S, Tochoedo NR, Vurnek D, Zink F, Hieronymus T. Clausen BE, et al. Among authors: nitsche d. Eur J Immunol. 2023 Dec;53(12):e2249925. doi: 10.1002/eji.202249925. Epub 2022 Dec 23. Eur J Immunol. 2023. PMID: 36563126
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators. Zhu AX, et al. Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18. Lancet Oncol. 2015. PMID: 26095784 Clinical Trial.
38 results